{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:48:07Z","timestamp":1790812087979,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,12,21]],"date-time":"2015-12-21T00:00:00Z","timestamp":1450656000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Galderma R&D"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>There are a limited number of approved treatments for papulopustular rosacea (<jats:styled-content style=\"fixed-case\">PPR<\/jats:styled-content>) and remission is difficult to maintain after successful treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To investigate remission over a 36\u2010week extension period in patients with moderate to severe <jats:styled-content style=\"fixed-case\">PPR<\/jats:styled-content> successfully treated with 16 weeks\u2019 treatment with ivermectin 1% cream once daily (<jats:styled-content style=\"fixed-case\">QD<\/jats:styled-content>) or metronidazole 0.75% cream twice daily (<jats:styled-content style=\"fixed-case\">BID<\/jats:styled-content>) in a randomized, parallel\u2010group <jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>hase <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content> study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Treatment was discontinued in patients initially successfully treated [Investigator's Global Assessment (<jats:styled-content style=\"fixed-case\">IGA<\/jats:styled-content>) score of 0 or 1] with ivermectin 1% cream <jats:styled-content style=\"fixed-case\">QD<\/jats:styled-content> (<jats:italic>n<\/jats:italic> = 399) or metronidazole 0.75% cream <jats:styled-content style=\"fixed-case\">BID<\/jats:styled-content> (<jats:italic>n<\/jats:italic> = 365; Part A) and patients were followed every 4 weeks for up to 36 weeks (Part B). Treatment with the same study treatment as used in Part A was only re\u2010initiated if patients relapsed (<jats:styled-content style=\"fixed-case\">IGA<\/jats:styled-content> \u2265 2). Efficacy assessments were: time to first relapse; relapse rate; and number of days free of treatment. Safety assessments included incidence of adverse events and local cutaneous signs and symptoms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median time to first relapse was significantly longer (115 days vs. 85 days) and relapse rates at the end of the study period significantly lower (62.7% vs. 68.4%) for patients initially successfully treated with ivermectin 1% compared with metronidazole 0.75%; <jats:styled-content style=\"fixed-case\">K<\/jats:styled-content>aplan\u2013<jats:styled-content style=\"fixed-case\">M<\/jats:styled-content>eier plot demonstrated a statistically significant difference between the two arms (<jats:italic>P<\/jats:italic> = 0.0365). The median number of days free of treatment was higher for ivermectin compared with metronidazole (196 days vs. 169.5 days; <jats:italic>P<\/jats:italic> = 0.026). The percentage of patients who experienced a related adverse event was equally low in both groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The results of this relapse study showed that an initial successful treatment with ivermectin 1% cream <jats:styled-content style=\"fixed-case\">QD<\/jats:styled-content> significantly extended remission of rosacea compared with initial treatment with metronidazole 0.75% cream <jats:styled-content style=\"fixed-case\">BID<\/jats:styled-content> following treatment cessation.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.13537","type":"journal-article","created":{"date-parts":[[2015,12,22]],"date-time":"2015-12-22T00:59:22Z","timestamp":1450745962000},"page":"829-836","source":"Crossref","is-referenced-by-count":46,"title":["Maintenance of remission following successful treatment of papulopustular rosacea with ivermectin 1% cream vs. metronidazole 0.75% cream: 36\u2010week extension of the <scp>ATTRACT<\/scp> randomized study"],"prefix":"10.1111","volume":"30","author":[{"given":"A.","family":"Taieb","sequence":"first","affiliation":[{"name":"Service de Dermatologie et Dermatologie P\u00e9diatrique H\u00f4pital Saint\u2010Andr\u00e9 Bordeaux Cedex France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Khemis","sequence":"additional","affiliation":[{"name":"Dermatology Department Centre Hospitalier Universitaire de Nice Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ruzicka","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy Ludwig Maximilian University Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Bara\u0144ska\u2010Rybak","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology Medical University of Gdansk Poland Gdansk Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Berth\u2010Jones","sequence":"additional","affiliation":[{"name":"Dermatology Clinical Research Unit Department of Dermatology George Eliot Hospital Nuneaton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Schauber","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy Ludwig Maximilian University Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Briantais","sequence":"additional","affiliation":[{"name":"Galderma R&amp;D Sophia Antipolis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Jacovella","sequence":"additional","affiliation":[{"name":"Galderma R&amp;D Sophia Antipolis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Passeron","sequence":"additional","affiliation":[{"name":"Dermatology Department Centre Hospitalier Universitaire de Nice Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Ivermectin Phase III Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,12,21]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"CD003262","article-title":"Interventions for rosacea","volume":"4","author":"Zuuren EJ","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.04.045"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.07.009"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.08.028"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.08.027"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.06.009"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-015-0077-2"},{"key":"e_1_2_6_9_1","first-page":"348","article-title":"Burden of disease: the psychosocial impact of rosacea on a patient's quality of life","volume":"6","author":"Huynh TT","year":"2013","journal-title":"Am Health Drug Benefits"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1976"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.05.036"},{"key":"e_1_2_6_12_1","unstructured":"National Rosacea Society.New Rosacea Survey Shows Emotional Toll of Facial Redness Equals Impact of Bumps Pimples 2014. Available at:http:\/\/www.rosacea.org\/press\/new-rosacea-survey-shows-emotional-toll-facial-redness-equals-impact-bumps-pimples(http:\/\/www.rosacea.org\/press\/new-rosacea-survey-shows-emotional-toll-facial-redness-equals-impact-bumps-pimples) (last accessed: 05 June 2015)."},{"key":"e_1_2_6_13_1","first-page":"16","article-title":"Advances in understanding and managing rosacea: part 1: connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema","volume":"5","author":"Rosso JQ","year":"2012","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_6_14_1","first-page":"694","article-title":"Why is rosacea considered to be an inflammatory disorder? The primary role, clinical relevance, and therapeutic correlations of abnormal innate immune response in rosacea\u2010prone skin","volume":"11","author":"Rosso JQ","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.14"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12030"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04310.x"},{"key":"e_1_2_6_18_1","unstructured":"Food and Drug Administration (FDA).SOOLANTRA\u2122prescribing information. December 2014."},{"key":"e_1_2_6_19_1","first-page":"73","article-title":"The CLEAR trial: results of a large community\u2010based study of metronidazole gel in rosacea","volume":"79","author":"Wolf JE","year":"2007","journal-title":"Cutis"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.308"},{"key":"e_1_2_6_21_1","first-page":"641","article-title":"Combined effect of anti\u2010inflammatory dose doxycycline (40\u2010mg doxycycline, usp monohydrate controlled\u2010release capsules) and metronidazole topical gel 1% in the treatment of rosacea","volume":"6","author":"Fowler JF","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1975.tb02252.x"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2009.00684.x"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.2183\/pjab.87.13"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pt.2014.07.005"},{"key":"e_1_2_6_26_1","unstructured":"European Medicines Agency (EMA).SOOLANTRA\u2122\u2013 summary of product characteristics. April 2015."},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-011-0307-8"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-008-8007-8"},{"key":"e_1_2_6_29_1","first-page":"316","article-title":"Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double\u2010blind, vehicle\u2010controlled pivotal studies","volume":"13","author":"Stein Gold L","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_30_1","first-page":"1380","article-title":"Long\u2010term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40\u2010week controlled, investigator\u2010blinded trials","volume":"13","author":"Stein Gold L","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13408"},{"key":"e_1_2_6_32_1","unstructured":"Galderma Ltd.Data on file."},{"key":"e_1_2_6_33_1","first-page":"41","article-title":"Healthcare utilization and costs of patients with rosacea in an insured population","volume":"7","author":"Romanowicz M","year":"2008","journal-title":"J Drugs Dermatol"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.13537","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.13537","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.13537","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T19:56:38Z","timestamp":1695498998000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.13537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,21]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1111\/jdv.13537"],"URL":"https:\/\/doi.org\/10.1111\/jdv.13537","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,21]]}}}